Shorter radiation treatment for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a shorter course of radiation therapy for up to 5 bone lesions that have come back or not responded to treatment. It aims to see if this approach is safe and helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has come back or not responded to treatment, with up to 5 bone spots that need radiation.
- You have had standard treatments for your myeloma before joining.
- Your tumor is between 0.25 cc and 65 cc (about the size of a pea to a large egg).
- You are able to take care of yourself (up to spending about half the day in bed).
- You are not pregnant, breastfeeding, or planning to become pregnant or father children during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a single dose of radiation can effectively relieve bone pain caused by multiple myeloma. It is designed for people who have a painful bone lesion and are stable on or off treatment.
This study is for people with newly diagnosed multiple myeloma whose cancer responded to initial treatment but still has tiny traces (minimal residual disease, or MRD). The trial will test if adjusting the next phase of therapy based on MRD levels can improve long-term outcomes.
This trial tests giving “salvage” radiation (radiation meant to control remaining cancer) after you’ve already had BCMA CAR-T therapy for multiple myeloma. It’s for people whose PET or other scan still shows active myeloma at least 30 days after CAR-T, and who have a spot that radiation can target.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.